Ultragenyx Pharmaceutical (NASDAQ:RARE) was downgraded by investment analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research note issued to investors on Saturday.

Other equities analysts have also issued reports about the stock. Raymond James set a $70.00 price target on shares of Ultragenyx Pharmaceutical and gave the company a “buy” rating in a research note on Friday, October 26th. ValuEngine lowered shares of Ultragenyx Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Friday, October 12th. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, August 29th. JMP Securities reiterated a “buy” rating and issued a $94.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Sunday, September 2nd. Finally, Zacks Investment Research upgraded shares of Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating and set a $86.00 price target on the stock in a research note on Wednesday, October 3rd. One analyst has rated the stock with a sell rating, six have assigned a hold rating and fifteen have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $76.17.

RARE stock opened at $46.66 on Friday. Ultragenyx Pharmaceutical has a fifty-two week low of $41.67 and a fifty-two week high of $90.98. The company has a market cap of $2.55 billion, a P/E ratio of -6.22 and a beta of 2.36.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings results on Monday, November 5th. The biopharmaceutical company reported ($1.74) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.94) by $0.20. The company had revenue of $11.80 million for the quarter, compared to analyst estimates of $11.97 million. Ultragenyx Pharmaceutical had a negative net margin of 508.70% and a negative return on equity of 40.10%. The firm’s revenue was up 5800.0% on a year-over-year basis. During the same period in the prior year, the firm posted ($1.87) earnings per share. As a group, analysts predict that Ultragenyx Pharmaceutical will post -3.99 EPS for the current fiscal year.

In other news, CFO Shalini Sharp sold 6,700 shares of the stock in a transaction that occurred on Tuesday, September 25th. The stock was sold at an average price of $90.07, for a total value of $603,469.00. Following the completion of the sale, the chief financial officer now directly owns 56,828 shares of the company’s stock, valued at $5,118,497.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director William Aliski sold 19,550 shares of the stock in a transaction that occurred on Monday, October 8th. The shares were sold at an average price of $72.49, for a total value of $1,417,179.50. Following the completion of the sale, the director now directly owns 72,610 shares of the company’s stock, valued at $5,263,498.90. The disclosure for this sale can be found here. Insiders sold 38,250 shares of company stock valued at $2,652,809 over the last three months. Corporate insiders own 8.40% of the company’s stock.

Hedge funds have recently bought and sold shares of the company. Swiss National Bank boosted its holdings in shares of Ultragenyx Pharmaceutical by 5.7% in the second quarter. Swiss National Bank now owns 82,052 shares of the biopharmaceutical company’s stock valued at $6,307,000 after acquiring an additional 4,400 shares during the period. Capital Impact Advisors LLC boosted its holdings in shares of Ultragenyx Pharmaceutical by 6.2% in the third quarter. Capital Impact Advisors LLC now owns 28,746 shares of the biopharmaceutical company’s stock valued at $2,295,000 after acquiring an additional 1,672 shares during the period. Metropolitan Life Insurance Co. NY boosted its holdings in shares of Ultragenyx Pharmaceutical by 7.3% in the second quarter. Metropolitan Life Insurance Co. NY now owns 15,187 shares of the biopharmaceutical company’s stock valued at $1,167,000 after acquiring an additional 1,037 shares during the period. American Century Companies Inc. boosted its holdings in shares of Ultragenyx Pharmaceutical by 52.4% in the second quarter. American Century Companies Inc. now owns 55,975 shares of the biopharmaceutical company’s stock valued at $4,303,000 after acquiring an additional 19,255 shares during the period. Finally, Cowen Inc. acquired a new stake in shares of Ultragenyx Pharmaceutical in the second quarter valued at approximately $1,537,000. 97.60% of the stock is owned by institutional investors and hedge funds.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.

Featured Story: Stock Selection – What is cash flow?

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.